Neurogene (NGNE) Projected to Post Earnings on Monday

Neurogene (NASDAQ:NGNE) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($1.20) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Neurogene Trading Down 0.7%

Shares of NASDAQ:NGNE opened at $19.05 on Friday. The stock has a market capitalization of $295.08 million, a PE ratio of -4.64 and a beta of 1.53. Neurogene has a 1 year low of $6.88 and a 1 year high of $37.27. The firm has a fifty day moving average price of $19.21 and a 200 day moving average price of $21.62.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NGNE. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research report on Tuesday, January 13th. Wall Street Zen cut shares of Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Canaccord Genuity Group began coverage on shares of Neurogene in a report on Friday, February 27th. They set a “buy” rating for the company. Finally, Lifesci Capital initiated coverage on shares of Neurogene in a report on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Neurogene presently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Insider Activity

In related news, CFO Christine Mikail Cvijic sold 4,045 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $84,176.45. Following the transaction, the chief financial officer directly owned 105,798 shares in the company, valued at $2,201,656.38. The trade was a 3.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Stuart Cobb sold 6,797 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $141,445.57. Following the sale, the insider owned 30,497 shares in the company, valued at approximately $634,642.57. This represents a 18.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 11.64% of the company’s stock.

Institutional Investors Weigh In On Neurogene

A number of institutional investors have recently bought and sold shares of NGNE. BNP Paribas Financial Markets lifted its holdings in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after acquiring an additional 978 shares during the period. ADAR1 Capital Management LLC increased its stake in Neurogene by 3.4% in the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after acquiring an additional 1,008 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in Neurogene during the fourth quarter worth about $66,000. Finally, Geode Capital Management LLC lifted its stake in Neurogene by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock worth $5,145,000 after purchasing an additional 3,262 shares during the period. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.